CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Definium Therapeutics Grants Options for 93,320 Shares to Six New Employees

By Public Technologies
  • Definium Therapeutics granted six newly hired non-executive employees options to purchase 93,320 common shares under its 2026 Inducement Plan.
  • The options carry an effective grant date of October 26, 2026, following Compensation Committee approval on October 23, 2026.
  • Vesting spans four years: 25% on the first grant anniversary, with the remaining 75% in substantially equal monthly installments over three years.
  • All vesting is subject to each employee’s continued employment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026727263) on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk